Here are the S-1 registration statements from Estrella Immunopharma, Inc. (ESLA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow ESLA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ESLA filings page.
Estrella Immunopharma, Inc. filed Amendment No. 2 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the registration statement unchanged and focuses on updating the list of exhibits.
The filing itemizes corporate documents such as the amended and restated charter and bylaws, various merger and financing agreements, equity incentive plans, employment agreements, and a warrant agreement, largely incorporated by reference from earlier filings. It also includes the legal opinion from Winston & Strawn LLP, consents from current and former auditors, XBRL-related exhibits, and powers of attorney.
The amendment is signed on behalf of Estrella Immunopharma by Chief Executive Officer Cheng Liu and lists the company’s principal officers and directors, confirming their authorization of the registration statement.
Estrella Immunopharma, Inc. is registering up to 9,236,141 shares of common stock for resale by existing selling stockholders, including shares already issued, contingent “true-up” and reset shares, and shares issuable upon exercise of warrants from recent private placements. The registered resale shares represent approximately 22.0% of total common stock outstanding as of January 11, 2026, creating potential stock overhang as these holders may sell over time.
Estrella will not receive proceeds from stockholder resales under this prospectus. A significant portion of the shares was or may be issued at effective prices below recent trading levels, which may incentivize sales at market prices. The company remains a clinical-stage, loss‑making cell therapy developer focused on its lead candidate EB103 for relapsed or refractory B‑cell malignancies, with an accumulated deficit of about $36.4 million as of September 30, 2025 and a disclosed need for substantial additional funding. Estrella is controlled by Eureka Therapeutics, which holds about 60.1% of the voting power.